tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
PremiumThe FlyY-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
11d ago
Hold Rating Issued Amidst SERB Pharmaceuticals’ Acquisition of Y-mAbs Therapeutics
Premium
Ratings
Hold Rating Issued Amidst SERB Pharmaceuticals’ Acquisition of Y-mAbs Therapeutics
11d ago
Y-mAbs Therapeutics downgraded to Hold from Buy at Truist
Premium
The Fly
Y-mAbs Therapeutics downgraded to Hold from Buy at Truist
11d ago
Palantir reports Q2 beat, Caterpillar posts mixed results: Morning Buzz
PremiumThe FlyPalantir reports Q2 beat, Caterpillar posts mixed results: Morning Buzz
12d ago
Y-mAbs Therapeutics downgraded to Neutral from Outperform at Wedbush
Premium
The Fly
Y-mAbs Therapeutics downgraded to Neutral from Outperform at Wedbush
12d ago
Y-Mabs Therapeutics Announces Merger with SERB Pharmaceuticals
Premium
Company Announcements
Y-Mabs Therapeutics Announces Merger with SERB Pharmaceuticals
12d ago
Promising R&D Developments and New Radiohapten Propel Y-Mabs Therapeutics to a Buy Rating
PremiumRatingsPromising R&D Developments and New Radiohapten Propel Y-Mabs Therapeutics to a Buy Rating
2M ago
Optimistic Outlook on Y-mAbs Therapeutics’ GD2-SADA Platform Despite Developmental Delays
Premium
Ratings
Optimistic Outlook on Y-mAbs Therapeutics’ GD2-SADA Platform Despite Developmental Delays
3M ago
Y-mAbs Therapeutics price target lowered to $15 from $20 at Oppenheimer
Premium
The Fly
Y-mAbs Therapeutics price target lowered to $15 from $20 at Oppenheimer
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100